Premium-PANAF antivenom for snakebite in Ethiopia
Official title: A Prospective Cohort Study of Polyvalent Antivenom (Premium-PANAF) for Snakebite Envenoming in Ethiopia
Run by Medecins Sans Frontieres, Netherlands · NCT07659002 · Data updated 2026-11-12
This study tests the safety and effectiveness of Premium-PANAF antivenom for people who have been bitten by snakes in Ethiopia.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | Medecins Sans Frontieres, Netherlands Academic / other |
| Locations | 1 site (Ābderafī, Amhara) |
| Status | Recruiting |
| Started | June 2, 2025 |
| Main results expected | August 1, 2026 |
| Study ends | September 1, 2026 |
| Registry record updated | June 22, 2026 |
| Trial ID | NCT07659002 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are snakebite patients in northwestern Ethiopia who receive Premium-PANAF and can give written informed consent.
✕Probably not a fit
Patients who do not receive Premium-PANAF or who have contraindications to its use may not experience benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational cohort study conducted at Abdurafi Health Center in Amhara, Ethiopia, led by MSF with collaboration from the University of Gondar. It follows patients who receive Premium-PANAF antivenom to document real-world safety and effectiveness after administration. The study uses prospective data collection to observe outcomes and any adverse events in a resource-limited setting where cold-chain requirements are minimized by the lyophilised product. It does not assign treatments or compare against other antivenoms, but aims to provide post-marketing pharmacovigilance information aligned with WHO recommendations. Enrollment is restricted to patients who receive Premium-PANAF and provide informed consent, with exclusions for those who did not receive the product or who cannot consent.
Why it matters
Potential benefit: If successful, the study could confirm real-world safety and effectiveness of Premium-PANAF in treating snakebite envenoming in Ethiopia.
How similar studies have gone: There is limited post-marketing data from similar real-world use; this observational cohort aims to contribute primary safety and effectiveness evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria * Snakebite envenoming patients who receive Premium-PANAF antivenom * Patients who have given written informed consent . Exclusion criteria * Snakebite envenoming patients who do not receive Premium-PANAF antivenom * Patients referred from other centres who already received other antivenom treatment * Patients who are unable or unwilling to give informed consent
Where it's running
-
Abdurafi Health Center
Ābderafī, Amhara, Ethiopia Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing pressure pad versus pressure bandage immobilisation for snakebite first aid in healthy adults
This test will see if a pressure pad works as well as the standard pressure bandage at slowing the spread of a mock venom in healthy adults.
-
Mapping snakebite risk in Ghana and Rwanda
This study tests whether geospatial methods can map and predict where snakebites happen, using hospital data and household surveys in Ghana and Rwanda.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.